Zheng Yan

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 5

Top Topics

Radiation Induced

Community Dwelling

Acute Lymphoblastic Leukemia

Top Venues

Cancer management and research

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

This page only lists publications with an associated author ORCID identifier.

Publications

Wenping Zhou, Yuanlin Xu, Jiuyang Zhang, Peipei Zhang, Zhihua Yao, Zheng Yan, Haiying Wang, Junfeng Chu, Shuna Yao, Shuang Zhao, Shujun Yang, Yongjun Guo, Jinxin Miao, Kangdong Liu, Wing C Chan, Qingxin Xia, Yan-Yan Liu
MiRNA-363-3p/DUSP10/JNK axis mediates chemoresistance by enhancing DNA damage repair in diffuse large B-cell lymphoma. Leukemia 36 (7) (2022)
Zheng Yan, Shuna Yao, Junhui Yuan, Yanyan Liu, Zhihua Yao
Multiple rechallenges with anti-PD-1 immunotherapy in patients with checkpoint inhibitor-related pneumonitis: A report of two cases. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2022)
Zheng Yan, Shuna Yao, Yuanyuan Wang, Yan-Yan Liu, Zhihua Yao
Primary Testicular Lymphoma with Central Nervous System Relapse Was Successfully Treated by a Chemo-Free Regimen: A Case Report and Literature Review. Cancer management and research 13 (2021)
Zheng Yan, Zhi-Hua Yao, Shu-Na Yao, Hai-Ying Wang, Jun-Feng Chu, Ming Song, Shuang Zhao, Yan-Yan Liu
Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma. Immunotherapy 12 (16) (2020)
Zheng Yan, Zhi-Hua Yao, Shu-Na Yao, Qing-Xin Xia, Hai-Ying Wang, Jun-Feng Chu, Ming Song, Shuang Zhao, Yan-Yan Liu
Combining PD-1 Inhibitor Nivolumab with Radiotherapy Successfully Treated a Patient with Refractory Primary Mediastinal Large B-Cell Lymphoma: A Case Report and Literature Review. Cancer management and research 12 (2020)